ClinicalTrials.gg
CompletedNCT04387461CORE-001Updated Sep 25, 2024

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

A Phase 2 interventional study of CG0070 and Pembrolizumab Injection in Non Muscle Invasive Bladder Cancer, sponsored by CG Oncology, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by CG Oncology, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Enrollment
59th of 93
35 · median 55
Started
2020
with 5 others
Phase 2
20 of 114
8 open now
Registered
46th of 114
by date
Lead sponsor
4 of 114
CG Oncology, Inc.

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 59th largest by enrollment of the 93 interventional ones that give a count, is one of 6 that started in 2020, is one of 20 in phase 2, and was the 46th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.

Read the detailed description

An opened label trial designed to evaluate CG0070 and DDM in combination with Pembrolizumab in patients with NMIBC who have failed prior BCG therapy.

The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1 papillary disease will be enrolled.

BCG failure is defined as persistent or recurrent disease within 12 months of completion of adequate BCG therapy.

03

Conditions studied

  • Non Muscle Invasive Bladder Cancer

Keywords

  • high-grade Ta papillary disease
  • high-grade T1 papillary disease
  • carcinoma in situ
  • Bacillus-Calmette-Guerin Unresponsive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status 0 to 2
  • confirmed NMIBC with CIS (with or without Ta/T1 disease)
  • Unresponsive to prior BCG therapy (Lerner 2015) defined as persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the sub- epithelial connective tissue) disease within 12 months of completion of adequate BCG therapy. An assessment within 15 months can also qualify when no assessment was performed within 12 months after completion of adequate BCG therapy.

    • Adequate BCG is defined as at least 5 treatments with induction BCG followed by at least 2 BCG treatments as reinduction or maintenance
  • Ineligible for radical cystectomy or refusal of radical cystectomy
  • Adequate organ function

Key Exclusion Criteria:

  • Immuno-deficient due to chronic or other use, , or prior organ transplant
  • Prior treatment with adenovirus-based cancer therapy
  • Prior therapy with or intolerant to prior therapy
  • or active cardiac disease
  • Active disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Single Arm

    CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g., complete response) then the patient will receive 3 weekly treatments. Beginning at Week 25, patients will receive weekly x 3 treatments every 3 months through Week 49 then every 24 weeks thereafter. Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 6 weeks for up to 2 years.

    Biological: CG0070 · Biological: Pembrolizumab Injection · Other: n-dodecyl-B-D-maltoside

Interventions

  • BiologicalCG0070

    Engineered Oncolytic Adenovirus

  • Immune checkpoint inhibitor, Monoclonal antibody

    Also known as: KEYTRUDA®

  • Othern-dodecyl-B-D-maltoside

    Transduction-enhancing agent.

    Also known as: DDM

06

What researchers measure

Primary outcomes

  1. Complete response rate in patients

    Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of adverse events when CG0070 administered intravesically when combined with pembrolizumab.

    Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0

    Time frame: 12 months

  2. Median duration of response (DoR)

    Median duration of response in patients with a CR or PR

    Time frame: 12 months

  3. Median overall survival (OS)

    Median overall survival in months in patients

    Time frame: 12 months

  4. Median progression free survival

    Median duration of progression free survival of patients

    Time frame: 12 months

07

Study locations

19 sites
  • University of California - San Diego
    La Jolla, California 92093, United States
  • University of California - Irvine
    Orange, California 92868, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwestern University
    Tampa, Florida 33612, United States
  • Johns Hopkins Medical Institution
    Baltimore, Maryland 21287, United States
  • Chesapeake Urology
    Hanover, Maryland 21076, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55902-9823, United States
  • New York University
    New York, New York 10003, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Keystone Urology Specialists
    Lancaster, Pennsylvania 17604, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Spokane Urology
    Spokane, Washington 99202, United States
  • Chonnam National University Hwasun Hospital
    Hwasun, 58128, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Severance Hospital
    Sinchon-dong, Korea, Republic of
  • Pusan National University Yangsan Hospital
    Yangsan, 50612, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Mar 2023, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2020
First posted
May 13, 2020
StartActual
Dec 8, 2020
Primary completionActual
Mar 7, 2023
CompletionActual
May 28, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04387461
Lead sponsor
CG Oncology, Inc.
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Dec 8, 2020
Primary completion
Mar 7, 2023
Completion
May 28, 2024
Last update
Sep 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cretostimogene grenadenorepvec

Start the discussion